RxDoctor Payments Data

Jack Brenner, MD

Gastroenterology · Yorktown Heights, NYNPI 1033287347

Payments from drug & device makers

$9,616in general payments, 2019–2025

Across 303 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Planmeca USA, Inc.$3K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$840
  • Lilly USA, LLC$481
  • Takeda Pharmaceuticals U.S.A., Inc.$472
  • Novo Nordisk$450
  • plus $2K from 29 others

What the payments were for

  • Speaking & faculty fees$3,47636%
  • Food & beverage$6,14064%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,616 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$28,235
Medicare patients
104
Services billed
301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$46,201
Mesalamine31$11,334
Dexlansoprazole DrDexlansoprazole14$3,625
Sucralfate17$2,934
Pantoprazole Sodium94$1,591
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates24$1,426
Famotidine54$921
Omeprazole40$668
Lansoprazole11$412
Rabeprazole Sodium11$155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$840$46,20114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Yorktown Heights

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →